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BACKGROUND: Hepatitis E virus (HEV) is a small,
nonenveloped, single-stranded, RNA virus of emerging
concern in industrialized countries. HEV transmission
through transfusion of blood components has been
reported, but not via plasma-derived medicinal products
(PDMPs) manufactured with virus inactivation and/or
removal steps. This study aimed to determine the
prevalence of HEV among US source plasma donors.
STUDY DESIGN AND METHODS: Samples were
collected from US source plasma donors at centers
across the United States and were initially screened for
HEV RNA in 96-sample minipools using the Roche cobas
HEV test on the cobas 8800 system. Assuming a
sensitivity of 18.6 IU/mL, the minipool screening strategy
allowed for reliable detection of individual donations with
HEV RNA titers of more than 23 103 IU/mL. Reactive
minipools were resolved to individual donations, which
were further analyzed to quantify viral RNA
concentration, determine HEV genotype, and
immunoglobulin (Ig)G and IgM HEV antibody status.
RESULTS: A total of 128,020 samples were collected
from 96 CSL Plasma centers in the United States,
representing 27 states. The prevalence of HEV RNA–
positive samples was 0.002% with three unique HEV-
positive donors identified, all HEV Subgenotype 3a. Virus
titers of HEV-positive samples were relatively low (103-
104 IU HEV RNA/mL). One positive donation was HEV
IgG seropositive.
CONCLUSION: Routine screening of US source
plasma donations for HEV would not substantially
improve the safety of most PDMPs. The low prevalence
and potential viral load of HEV, together with effective
virus reduction steps in manufacturing processes, results
in a low residual risk and acceptable safety margins for
PDMPs derived from US plasma donors.
H
epatitis E virus (HEV) is a small (27-34 nm),
nonenveloped, single-stranded RNA virus.
Globally, HEV is the most common cause of
acute hepatitis, which is usually benign, but
fulminant cases have been seen in pregnant women and
patients with existing liver disease. In immunosuppressed
patients, there is a risk of progression to a chronic state.1
There is one serotype but four genotypes with varying
geographic distribution and epidemiologic and clinical
features.1,2 Genotypes 1 and 2 are most commonly associ-
ated with water-borne epidemics and were estimated to
account for 20 million incident infections, 3 million cases
of acute disease, and 70,000 deaths worldwide in 2005.3
Genotypes 3 and 4 occur most commonly in swine. Thus,
infection in humans can result from transmission through
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food, especially raw or undercooked pork products con-
taining liver or blood.1
In the United States, data from the Third National
Health and Nutrition Examination Study (NHANES III),
covering the period from 1988 to 1994, reported a 21%
prevalence of immunoglobulin (Ig)G antibody to HEV and
seven incident infections per 1000 susceptible persons per
year. However, the 2009 to 2010 survey showed a seroprev-
alence of only 6%. Possible reasons for this difference
could be assay performance, differences between an older
population with infection in the remote past and younger
populations, lifestyle or behavioral changes, or a change
in the etiologic agent.4 These data also suggest a lower
prevalence of HEV in the United States than other parts of
the world.5
HEV incidence and prevalence among blood donors
has become a concern since the disease can be transmit-
ted through blood transfusion. In Southeast England,
Genotype 3 infections were found to be widespread in
blood donors with an RNA prevalence of 1 in 2848.6
Among German blood donors, seroprevalence of HEV was
6.8% with an annual incidence of 0.35%.7 In the Nether-
lands, HEV seroprevalence has been reported as 27%,8
and one in 762 blood donations were HEV RNA positive.9
Seroprevalence has been reported as 10.7% in Danish
blood donors.10 In Southwest France, IgG seroprevalence
was found to be 52.5% among blood donors with the
endemic nature of HEV believed to be related to local die-
tary habits.11 Among US American Red Cross donors low
rates were found: HEV RNA prevalence of one in 9500 and
anti-HEV prevalence of 7.7%.12
Many countries have begun HEV RNA virus screening
programs for donated blood.13 This has naturally led to
the question of whether source plasma donation should
also be screened, particularly since detection of HEV in
manufacturing pools has been reported.14 In the United
States, source plasma donors are able to donate 400 to
800 mL of plasma a maximum of twice per week, with at
least 2 days between donations.15 Donors must be
healthy; negative for human immunodeficiency virus
(HIV), hepatitis B virus (HBV), and hepatitis C virus
(HCV); not involved in any high-risk behaviors; and not
be showing any signs of fever.16,17
Dedicated virus reduction steps in manufacturing of
plasma-derived medicinal products (PDMPs) are expected
to be effective in mitigating the risk of virus transmission
from plasma derivatives. However, it is necessary to know
the anticipated virus load of the plasma pooled for manu-
facture to perform a risk assessment. Since the majority of
the plasma used for manufacture of plasma derivatives
worldwide comes from US donors, the prevalence of HEV
among US-source plasma donors needs to be determined.
Thus, we performed this study to evaluate the incidence
of HEV in US-source plasma donors and to characterize
any HEV-reactive samples identified.
MATERIALS AND METHODS
This study aimed to screen a minimum of 125,000 donors,
to determine the prevalence of HEV among US source
plasma donors. This target was selected, based on all
existing data on HEV prevalence in the United States, to
ensure a high probability of detecting one or more posi-
tives. To achieve a broad geographical distribution, sam-
ples were collected from donors at 96 Food and Drug
Administration (FDA)-licensed CSL Plasma donor centers
in the United States, from July 20 through August 9, 2015.
The location of study collection centers is shown in Fig. 1.
The study was approved by the Copernicus Group
Institutional Review Board with a waiver for consent. All
samples were delinked, thereby preventing a sample being
traced back to the donor. However, samples could be
traced back to the collection center to identify the
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Study collection center with HEV-positive donation
Region Number 
of centers
Number of 
donors 
screened
Number
HEV 
positive
Midwest 32 45,698 3*
Southeast 25 27,740 0
West 12 16,317 0
Northeast 0 0 0
Southwest 27 38,265 0
Total 96 128,020 3
*posive samples obtained from centers in Fort Wayne, 
IN, Racine, WI and Columbus, OH
Fig. 1. Location of study collection centers and number of donors screened by region.
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geographic origins of any positives. This was accomplished
with prelabeled tubes with a specific numbering sequence.
The number of prelabeled study tubes provided to
each center was based on historical donor trends for each
site to meet the minimum collection target of more than
125,000 unique donations from unique donors within a 2-
to 3-week window. When the supply of tubes at any center
was exhausted, the study ended at that center. Upon initi-
ation of the study, the donor management system issued
an electronic “flag” requesting that the donor center col-
lect an additional 6 mL from the first donation made by
the donor during the study period. During subsequent vis-
its the electronic study “flag” disappeared from the donor
management system and no prompt for an additional
study-related sample was issued.
Minipools of 96 samples were created using an
instrument for automated plasma sample pooling and
pipetting (cobas p 680, Roche Molecular Systems), and
testing was performed on a molecular testing system
(cobas 8800, Roche Molecular Systems) using the cobas-
HEV nucleic acid test (NAT; Roche Molecular Systems)
under an investigational protocol following the manufac-
turer’s instructions. The cobas HEV test is commercially
available in countries that accept the CE mark where it
has a reported limit of detection of 18.6 IU/mL (95% con-
fidence interval [CI], 15.9-22.9 IU/mL) HEV RNA (probit
analysis), following the manufacturer’s instructions. Reac-
tive minipools were resolved and tested in minipools of 12
samples and finally individual donations to identify the
individual HEV-reactive samples. The cobas-HEV test
claimed sensitivity of 18.6 IU/mL assures that, during
minipool testing, individual positive donations with viral
loads of approximately 1800, 225, and 18.6 IU/mL would
reliably be detected (>95% CI) for minipools of 96, 12,
and individual samples, respectively. The cobas-HEV NAT
is not commercially available or approved by the FDA for
use in the United States, but the test is CE marked and
available for use in countries that accept the CE mark.
Testing was done at CSL Plasma Laboratory.
HEV RNA–reactive samples were further analyzed to
quantify the levels of HEV RNA using real-time reverse
transcription polymerase chain reaction (RT-PCR) (Taq-
Man Fast Virus 1-Step Master Mix, ThermoFisher
Scientific) in combination with published HEV-specific
primers.18 Samples were extracted using the viral nucleic
acid kit (High Pure, Roche Diagnostics) and amplified on a
real-time PCR instrument (Model 7500, Life Technologies).
HEV RNA levels were quantified against a standard curve
for the HEV-positive plasma donation, 054915007GO, cali-
brated against the World Health Organization HEV stan-
dard, at CSL Behring Laboratories. HEV RNA titers were
verified by independent testing at the Institute of Clinical
Microbiology and Hygiene, University Medical Center
Regensburg.
HEV RNA–positive samples were genotyped by ampli-
fying regions of ORF1 and ORF2 using real-time quantita-
tive PCR and sequence determination of the resulting
nucleic acid fragments, as described elsewhere.19 Sequen-
ces were evaluated with Fasta36 against GenBank to deter-
mine the phylogenetic map for the positive samples. A
maximum likelihood phylogenetic consensus tree of
ORF1 sequences was constructed by using computer soft-
ware (RAxML, Version 8.2.7).20 Bootstrap values (%) were
calculated from 650 bootstrap replicates.
IgG reactivity was determined using the HEV IgG
enzyme-linked immunosorbent assay (ELISA; Wantai)
according to the manufacturer’s instructions. IgG reactiv-
ity was confirmed and IgM reactivity was determined
using the HEV IgM and HEV IgG immunoblot (Mikrogen),
respectively. Avidity of IgG was determined by using an
HEV IgG immunoblot (recomLine, Mikrogen) and the
HEV ELISA (Wantai).
Measuring avidity by immunoblot was performed
with two test strips in parallel. After incubation with
plasma, both test strips were washed five times with wash
buffer whereas the avidity test strip was incubated with
wash buffer containing 6 mol/L urea during the second
washing step. Soak times were 3 minutes for the second
washing step and 5 minutes for the remaining four. Avidity
was quantified by determining the signal-to-cutoff ratio
(SCR) of the O2CGt3 band for both the untreated and
avidity reagent–treated replica blots.
Measuring avidity by ELISA was performed as previ-
ously described21 by following a protocol published by
Bendall and colleagues.22 Briefly, plasma was tested in
duplicates, whereby one duplicate was tested according to
the manufacturer’s instructions. The other duplicate was
tested by using wash buffer containing 5 mol/L urea for
the first two washing steps after serum incubation. Soak
times were 5 minutes for the first two washing steps and
30 seconds for the following wash steps. Avidity was calcu-
lated as 100% 3 SCRtreated/SCRuntreated for both methods.
Serologic tests for other virologic markers and bacterial
markers were performed to clarify the relationship
between two HEV RNA–reactive samples from the same
plasma collection center and with identical nucleic acid
sequences (see Appendix S1 and Table S1, available as sup-
porting information in the online version of this paper).
RESULTS
Sample collection, HEV screening, and sample
resolution
Samples were collected across 96 FDA-licensed CSL
Plasma US centers over the period of July 20 through
August 9, 2015, representing 27 states and more than 90%
of CSL Plasma centers. The number of donors from each
region is shown in Fig. 1.
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Primary screening of samples was typically performed
in minipools of 96 samples. In a small percentage of tests,
smaller sample pools or individual donations were
screened. A total of 128,026 donor samples underwent pri-
mary screening with 128,021 producing a final valid result.
The five results that were invalid were not considered for
further analysis. Of the 1352 valid primary pool tests (96-
sample minipools), five returned a reactive result. Four of
the five reactive primary pools were confirmed as positive
during 12-sample minipool resolution testing, with a
single-donor sample from each primary pool confirmed as
reactive when resolved to the individual sample testing
level (four of 128,021 [0.003%]). To verify that a false posi-
tive had been obtained in the fifth reactive 96-donor pool,
all eight 12-donor minipools were further resolved to the
single donation level and retested; all samples returned a
negative result. The frequency of false-reactive primary
pools was, therefore, one in 1352 (0.07%).
Of the four positive confirmed donations, one origi-
nated from Fort Wayne, Indiana; one from Racine, Wiscon-
sin; and two from a single center in Columbus, Ohio. The
unexpected yield of two positive donations from the same
center prompted an investigation to ensure that the sam-
ples were drawn from unique donors. The delinked study
design prevented direct confirmation; however, an extensive
evaluation of viral load, genotyping, and serologic profile of
the two plasma samples led to the conclusion that the two
samples represented a single individual donor. The investi-
gation and results are described in full in Appendix S1.
Determination of HEV RNA titers of reactive
samples
RNA titers of the three individual positive samples are
shown in Table 1. Comparable results were obtained by
independent testing at the Institute of Clinical Microbiol-
ogy and Hygiene at the University Medical Center Regens-
burg (data not shown).
HEV genotyping of reactive samples
All reactive samples were identified as HEV Subgenotype
3a, based on nucleic acid fragments of ORF1 and ORF2,
and were more than 87% identical (Fig. 2).
TABLE 1. RNA titers of HEV-reactive donations
determined by RT-qPCR
Sample number RNA titer 6 SD (log IU/mL)
0065 HEV 1068 3.8 6 0.1
0089 HEV 0499 3.0 6 0.1
0409 HEV 0331 3.4 6 0.1
RT-qPCR5 real-time quantitative PCR.
0065 HEV 1068
0089 HEV 0499
AB605196
AB605207
100
32
31
19
19
19
62
AB196842
3aAF060668
3aAF336002
22
EU879110
31 10
33
GU479457
EU718647
FR846453
JN701457
46 66
53
73
84
3jAY115488
3jAF521654
3bAB108662
3bAB189071
34
48
60
3cAF336007
3cAF336001
3cAF336013
49
64
85
3hAF215661
3hAF110387
HEV -3a
0409 HEV 0331
Fig. 2. Maximum likelihood phylogenetic consensus tree of ORF1 sequences showing the genotype of HEV-reactive samples.
ORF1 sequences from all HEV-reactive samples cluster with HEV Genotype 3, Subgenotype 3a. Numbers at the nodes indicate
bootstrap values (%) calculated from 650 bootstrap replicates. [Color figure can be viewed at wileyonlinelibrary.com]
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HEV serologic characterization of reactive samples
One of the three HEV-reactive samples (0065 HEV 1068)
was IgG positive on HEV IgG ELISA and IgG reactivity was
confirmed by IgG immunoblot. Avidity testing of the IgG-
positive sample showed a high avidity by immunoblot
(84%) and by ELISA (80.4%). All three samples were IgM
negative on immunoblot. These results are consistent
with a pattern of reinfection for 0065 HEV 106823 and new
infection for the other two HEV-reactive samples. Serology
results for the three HEV-reactive samples is shown in
Table 2.
DISCUSSION
Our data provide the first large-scale survey of the preva-
lence of HEV infection, as defined by HEV RNA, in US
source plasma donors. We identified three unique HEV-
positive donors out of approximately 128,000 donations,
resulting in a frequency of around one in 42,000 donations
(0.002%) being HEV positive. This frequency is lower than
that reported for US blood donors (one in 9500)12 but criti-
cal differences in HEV RNA screening strategies exist
between the two studies. Stramer and colleagues12
screened individual donations, thereby identifying positive
donations with HEV viral loads as low as 10 to 20 IU/mL.
Our HEV screening paradigm was based on a 96-
donation minipool strategy designed to reliably identify
donations with HEV viral loads of approximately 2000 IU
HEV RNA/mL or higher. This minipool screening strategy
is consistent with routine NAT methods currently used to
screen source plasma for HIV, HBV, and HCV. The HEV
RNA titers for the three positive donations were relatively
low and just sufficient to exceed the threshold level of the
minipool screening strategy and reliably be detected.
Additional donations with lower HEV RNA titers may have
been detected, if a 12-unit minipool or single-unit dona-
tion screening strategy had been utilized. Therefore, it is
possible that the HEV prevalence identified in this study is
an underestimation of the true figure, as additional HEV-
reactive donations may have been identified if single unit
donations were screened. However, the difference is likely
to be so small as to have little, if any, bearing on the con-
clusions made here.
During the study, two HEV-reactive donations from
the same collection center, which mapped identically on
phylogenetic analysis and had similar RNA titers, were
identified. Extensive serologic profiling indicated that the
samples came from the same donor. This may have
occurred due to a laboratory or procedural error and
delinking of the samples prevented them from being
traced back to the donor, unlike in routine operations.
Based on an audit of the study procedures, this was con-
sidered to be an isolated or extremely rare event, not
believed to impact on the conclusions of the study or its
scientific integrity.
The safety of PDMPs relies on the complementary
approach of 1) donor selection, 2) testing of plasma dona-
tions and plasma pools for the presence of certain viruses,
and 3) effective virus inactivation and removal steps
within the manufacturing processes, with a high capacity
to clear a broad variety of viruses. Of these complemen-
tary safety measures, arguably the most important step in
assuring the pathogen safety of PDMPs from emerging
viruses are manufacturing processes with robust and high
virus reduction capacity. During the early phases of the
emergence of a virus into the donor population, suitable
virus screening tests may not be available or approved by
regulatory authorities. Additionally, donor selection may
be only partly effective. Source plasma is only collected
from qualified healthy donors with low-risk behavior,
from geographical regions with acceptable epidemiologic
risk for HIV, HBV, and HCV; however, certain viruses such
as Zika virus (ZKV), West Nile virus (WNV), or HEV, may
result in mild or asymptomatic infections in blood and
plasma donors. Donors with mild symptomatic infections
would be deferred, but asymptomatic donors with no risk
factors would remain eligible to donate. Nonetheless,
recent history has shown that for certain emerging viruses,
such as WNV, and presumably ZKV, effective virus reduc-
tion steps in combination with even partially effective
donor screening measures is sufficiently robust to assure
the safety of PDMPs even in the absence of NAT for
screening of donations or plasma pools.24 In contrast,
nonvirally inactivated blood components are susceptible
to transmission of WNV and ZKV in the absence of NAT
within screening measures.
The likelihood (or margin of safety) that the final
PDMP is essentially “sterile” from infectious viruses can
be calculated according to European regulatory guidance
and depends on a variety of factors including epidemiol-
ogy of the virus in the donor population, donor frequency,
TABLE 2. Serology of HEV-reactive donations
Sample number IgG ELISA (IU/mL) IgG immunoblot IgM immunoblot IgG avidity (%)
0065 HEV 1068 0.6 Positive Negative 84.0 (immunoblot), 80.4 (ELISA)
0089 HEV 0499 Negative Negative Negative NA
0409 HEV 0331 Negative Negative Negative NA
NA5not applicable.
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virus life cycle, virus titer in blood, product yield, starting
pool size, and virus reduction capacity of the process for
the virus in question. In addition, since not all virions may
be packaged correctly or efficiently produce an infection
in vivo, the clinical experience on the minimum infectious
dose needed to produce an infection, that is, from blood
component lookback studies, can also be considered in
determining the margin of safety.25 Based on the clinical
experience in humans from unscreened blood compo-
nents, a minimum infectious dose of 2 3 104 IU HEV RNA
can be assumed.26
The low prevalence of HEV in the source plasma
donor population suggests that, on average, not more
than one HEV viremic donor’s donations would be
expected to enter a manufacturing pool. Although the
units identified in this survey had moderate titers, a highly
viremic unit with titers of approximately 106 IU/mL9
could potentially enter a manufacturing pool of several
thousand liters at a low frequency, which after dilution in
the starting pool would result in a maximum HEV RNA
titer of approximately 103 IU/mL, as reported by Baylis
and coworkers.14
In the case of B19V, individual viremic units can har-
bor titers as high as 1014 IU DNA/mL,27 which would
result in maximum pool titers in the order of 1010 IU/mL
B19V DNA in the absence of NAT screening. However,
safety margins in the order of 5 to 6 log are achieved for
B19V by performing minipool NAT screening, excluding
highly viremic B19V units from entering the plasma pool,
and the establishment of a plasma manufacturing pool
limit of not more than 104 IU B19V DNA/mL.28 In con-
trast, for HEV the relatively low maximum virus titer in
individual units and manufacturing pools, in the absence
of routine NAT, substantially limits the benefit that would
be attainable (approx. 1-2 log) utilizing a NAT screening
strategy consistent with the established commercial NAT
platforms employed for testing high volumes of source
plasma.
Multiple studies have confirmed that existing virus
inactivation and removal steps considered to be effective
(providing in the order of >4-log reduction) against rela-
tively resistent small nonenveloped viruses are also effec-
tive for HEV.29-31 In addition, manufacturing purification
steps also have the potential to significantly contribute to
reduction of HEV (approx. 1-3 log) through partitioning
mechanisms.29-31 Thus, for the vast majority of plasma-
derived products, the routine implementation of HEV
NAT of US source plasma would not contribute substan-
tially to the safety of the final product. Only in a few cer-
tain processes, where insufficient HEV reduction capacity
may exist, would donation and/or donor screening pro-
vide a significant contribution to the safety of the final
product.
In conclusion, in this first, large-scale survey of HEV
among US source plasma donors, HEV prevalence was
found to be very low. One donor had serology markers
and HEV IgG avidity consistent with a reinfection. The
low HEV RNA prevalence provides reassuring epidemio-
logic data regarding the low likelihood of a maximally
viremic HEV unit entering a plasma manufacturing pool.
Most PDMP manufacturing processes include virus reduc-
tion steps capable of removing or inactivating HEV
thereby resulting in a low residual risk and acceptable
safety margins for the final products. In select processes,
where HEV virus reduction may be limited, NAT screening
of donations and/or manufacturing pool testing could be
considered to provide additional safety margins in the
order of 1 to 2 log. The results of this study are consistent
with the conclusions of the European Medicines Agency
reflection paper on the viral safety of PDMPs with respect
to HEV and do not support a benefit from routine screen-
ing for HEV of all US source plasma donations or plasma
pools intended for manufacturing into PDMPs.
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Appendix S1. Investigation into the origin of two HEV-
reactive samples
Table S1. Serological profile of two HEV-reactive sam-
ples from the same center with identical nucleic acid
sequences
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